Asset Details
Do you wish to reserve the book?
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Do you wish to request the book?
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
2011
Overview
In this randomized trial of fidaxomicin as compared with vancomycin in 629 patients, oral fidaxomicin was shown to be noninferior to oral vancomycin in the treatment of
C. difficile
infection and was associated with lower rates of recurrence.
Clostridium difficile
infection generally occurs after exposure to broad-spectrum antibiotics. The incidence and severity of
C. difficile
infection are increasing. The increases have been ascribed to the emergence of a hypervirulent
C. difficile
strain, known variously as North American Pulsed Field type 1 (NAP1), restriction-endonuclease analysis (REA) type BI, or polymerase-chain-reaction ribotype 027 (referred to collectively as the NAP1/BI/027 strain).
1
–
4
Furthermore, the rates of death associated with
C. difficile
infection are rising,
5
–
7
and the infection is occurring in populations that were previously considered to be at low risk, such as young, healthy persons living in the community and . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Aminoglycosides - adverse effects
/ Aminoglycosides - pharmacokinetics
/ Aminoglycosides - therapeutic use
/ Anti-Bacterial Agents - adverse effects
/ Anti-Bacterial Agents - pharmacokinetics
/ Anti-Bacterial Agents - therapeutic use
/ Antibiotics. Antiinfectious agents. Antiparasitic agents
/ Biological and medical sciences
/ Clostridium difficile - classification
/ Clostridium difficile - drug effects
/ Clostridium difficile - isolation & purification
/ Clostridium Infections - drug therapy
/ Enterocolitis, Pseudomembranous - drug therapy
/ Female
/ Gastroenterology. Liver. Pancreas. Abdomen
/ Humans
/ Male
/ Pharmacology. Drug treatments
/ Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
/ Vancomycin - adverse effects
